Cargando…

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond

SIMPLE SUMMARY: Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in prostate cancer and correlates with the aggressiveness of the disease. PSMA is a promising target for imaging and therapeutics in prostate cancer patients validated in prospective trials. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hyväkkä, Anniina, Virtanen, Verneri, Kemppainen, Jukka, Grönroos, Tove J., Minn, Heikki, Sundvall, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125679/ https://www.ncbi.nlm.nih.gov/pubmed/34067046 http://dx.doi.org/10.3390/cancers13092244

Ejemplares similares

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
por: Virtanen, Verneri, et al.
Publicado: (2019)

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
por: Hyväkkä, Anniina, et al.
Publicado: (2022)

Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with (68)Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer
por: Ettala, Otto, et al.
Publicado: (2019)

Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
por: Schollhammer, Romain, et al.
Publicado: (2023)

Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy
por: Barqawi, Al B., et al.
Publicado: (2012)

What’s behind (68)Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
por: Rüschoff, Jan H., et al.
Publicado: (2021)

Single Center Experience with a 4-Week (177)Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Kemppainen, Jukka, et al.
Publicado: (2022)

Kinetic analysis and optimisation of (18)F-rhPSMA-7.3 PET imaging of prostate cancer
por: Malaspina, Simona, et al.
Publicado: (2021)

PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?
por: Lauri, Chiara, et al.
Publicado: (2022)

Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer
por: Virtanen, Verneri, et al.
Publicado: (2023)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
por: Cereser, Lorenzo, et al.
Publicado: (2023)

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
por: Gauthé, Mathieu, et al.
Publicado: (2021)

Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts
por: Tuomela, Johanna, et al.
Publicado: (2010)

A randomised, prospective and head-to-head comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale
por: Alberts, Ian, et al.
Publicado: (2022)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

PSMA-PET in the early stages of prostate cancer
por: Barbosa, Felipe de Galiza
Publicado: (2023)

PSMA-targeted therapy for non-prostate cancers
por: Wang, Jarey H., et al.
Publicado: (2023)

Flare on [(18)F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients
por: Malaspina, Simona, et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
por: Leung, Kevin H., et al.
Publicado: (2022)

Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET
por: Grönroos, Tove J, et al.
Publicado: (2014)

Cancers and Benign Processes on (68) Ga PSMA PET-CT Imaging Other than Prostate Cancer
por: Ozcan, Pinar Pelin, et al.
Publicado: (2022)

Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI—a phase I/II study
por: Beheshti, Mohsen, et al.
Publicado: (2022)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile
por: Boinapally, Srikanth, et al.
Publicado: (2021)

(11)C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial)
por: Salminen, Antti, et al.
Publicado: (2018)

PSMA diagnostics and treatments of prostate cancer become mature
por: von Eyben, Finn Edler, et al.
Publicado: (2018)

Clinical perspectives of PSMA PET/MRI for prostate cancer
por: Barbosa, Felipe de Galiza, et al.
Publicado: (2018)

On the Way for Patients with Prostate Cancer to the Best Use of PSMA
por: von Eyben, Finn Edler, et al.
Publicado: (2022)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer
por: Meher, Niranjan, et al.
Publicado: (2023)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

PSMA PET imaging in the diagnosis and management of prostate cancer
por: Houshmand, Sina, et al.
Publicado: (2023)

The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer
por: Kase, Adam M., et al.
Publicado: (2022)

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
por: Topoozian, Mark, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2df5m8lq9ht5bpu2s8khlieii0